Bacteriocide: Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin
Study Details
Study Description
Brief Summary
Phase I clinical study to compare the pharmacokinetic profiles and bactericidal activity of Zabofloxacin 183mg, 367mg and Levofloxacin 250mg after oral administration in healthy volunteer
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
A Randomized, open label, single dose, crossover phase I clinical study to compare the pharmacokinetic profiles and bactericidal activity of Zabofloxacin 183mg, 367mg and Levofloxacin 250mg after oral administration in healthy volunteer
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: A Group 1st oral administration of Zabofloxacin 183mg, 2nd oral administration of Zabofloxacin 367mg and 3rd oral administration of Levofloxacin 250mg |
Drug: Zabofloxacin 183mg
Zabofloxacin 183mg single dose
Other Names:
Drug: Levofloxacin 250mg
Levofloxacin 250mg single dose
Other Names:
Drug: Zabofloxacin 367mg
Zabofloxacin 367mg single dose
Other Names:
|
| Experimental: B Group 1st oral administration of Zabofloxacin 367mg, 2nd oral administration of Levofloxacin 250mg and 3rd oral administration of Zabofloxacin 367mg |
Drug: Zabofloxacin 183mg
Zabofloxacin 183mg single dose
Other Names:
Drug: Levofloxacin 250mg
Levofloxacin 250mg single dose
Other Names:
Drug: Zabofloxacin 367mg
Zabofloxacin 367mg single dose
Other Names:
|
| Experimental: C Group 1st oral administration of Levofloxacin 250mg, 2nd oral administration of Zabofloxacin 183mg and 3rd oral administration of Zabofloxacin 367mg |
Drug: Zabofloxacin 183mg
Zabofloxacin 183mg single dose
Other Names:
Drug: Levofloxacin 250mg
Levofloxacin 250mg single dose
Other Names:
Drug: Zabofloxacin 367mg
Zabofloxacin 367mg single dose
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Cmax and AUC [Predose(0), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours]
Maximum of Concentration(Cmax) Area Under Plasma Concentration-Time Curve(AUC)
Secondary Outcome Measures
- Pharmacokinetic Profile of Plasma [Predose(0), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours]
Maximum drug concentration time(Tmax) Half-time(t1/2) Apparent renal clearance(CL/F) Apparent volume of distribution(Vz/F) Mean of Retention Time(MRT)
- Pharmacokinetic Profile of Urine [Predose(-12-0), 0-6, 6-12, 12-24, 24-36, 48-72, 72-96, 96-120 hours]
Umax, Cumulative Amount Excreted(Ae), Fraction of the dose excreted unchanged(fe), Renal Clearance(CLr), Urinary Hydrogen exponent(Urinary pH)
- Bactericidal Activity Profile of Urine [Predose(-12-0), 0-6, 6-12, 12-24, 24-36, 48-72, 72-96, 96-120 hours]
Urinary Bactericidal Titers(UBT) Area under the UBT-versus-time curve(AUBT)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
A healthy adult within the range of 19 to 65 years old at the time of screening
-
Body Mass Index(BMI)=17.5~30.5kg/m2, one with weight of more than 55kg (BMI= kg/(m)2)
-
Congenital or chronic diseases within the last three years, there is no medical examination results of popular characters with no psychotic symptoms or findings
-
Doctor checks conducted hematology, blood chemistry, urinalysis and laboratory tests, including an electrocardiogram(EKG) performed during screening tests such as a suitable test subjects who judged
-
The purpose of the test participants prior to testing, information, and to hear about the free will fully explain to participate in this study, according to the Institutional Review Board(IRB)-approved consent form signed by the parties in writing
Exclusion Criteria:
-
One with clinically significant blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic disease (but ,except for untreated seasonal allergies of asymptomatic at the time of administration) with medical history or evidence
-
One with gastrointestinal disease(Such as esophageal stricture or achalasia of the esophagus disease, Crohn disease) to affect drug absorption or surgery(but, excluding simple appendectomy or hernia surgery) with medical history
-
Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) > 2 times the upper limit of the normal range
-
Within 6 months, 210 g / week of alcohol in excess of a history of regular characters (beer (5%) 1 cup (250 mL) = 10 g, soju(20%) 1 cup (50 mL) = 8 g, Wine (12%) 1 cup (125 mL) = 12 g)
-
Take part in other clinical trials within two months
-
Systolic Blood Pressure(SBP) ≥ 140 mmHg or Diastolic Blood Pressure (DBP) ≥ 90 mmHg
-
The great history of alcohol or drug abuse within 1 year
-
Taking medication of drug-metabolizing enzymes that are known to significantly induce or inhibit within 30 days
-
More than 20 cigarettes a day smoker
-
Taking medication of a prescription drug or nonprescription within 10 days,
-
Within two months the whole blood donation have, within one month of the apheresis donation have
-
Participate in clinical trials to test drug administration and may be at increased risk due to interpretation of test results, or may interfere with severe supply / chronic medical or mental condition or abnormal laboratory test values in character
-
Pregnant women and lactating mothers
-
Described lifestyle in this protocol can comply with or can not
-
One with other investigator judge to unsuitable
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Chonbuk National University Hospital | Jeonju | Jeollabuk-do | Korea, Republic of | 561-712 |
Sponsors and Collaborators
- Dong Wha Pharmaceutical Co. Ltd.
Investigators
- Principal Investigator: MinGul Kim, M.D, Chonbuk National University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DW224-I-7